McGill University

The funds will be used to develop organoids that can personalize treatments for cancer patients as well as other tools and resources.

Canadian construction firm Pomerleau gave the funds to support a program, in which researchers hope to advance a test predictive of colorectal cancer patients' outcomes.

The partnership aims to develop a test that will determine which patients with advanced colorectal cancer will not respond to standard treatment.